Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should invest ...

A New Orleans-based biotech company has developed a breakthrough non-opioid pain medication, which is backed by funding from Ochsner Ventures, the investment arm of Ochsner Health, and from Gulf South ...

Purple Biotech Ltd. announced it is advancing NT219, a novel drug aimed at overcoming tumor resistance to therapy, into a Phase 2 clinical trial for patients with recurrent/metastatic squamous cell ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of 2020 and 2021 and an anticipated stock recovery in 2024 failed to materialise.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of ...

Once upon a time, Moderna was a shooting star whose success relied on the COVID-19 vaccine, but now advances in an RSV vaccine could mean more success for the pharmaceutical and biotechnology company.

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to ...

Bacterial sensory systems represent a dynamic and rapidly evolving area at the intersection of molecular microbiology and biochemistry, where recent ...

POTOMAC (ACCESS Newswire) — IGC Pharma Inc., a Potomac-based clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease and metabolic disorders, ...

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best US stocks to buy under $50. On January 15, analysts at Deutsche Bank reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and ...